Hausärzte Dres. Erlinger & Kollegen
- Address
- Hechtstr 66, 70378 Stuttgart, Germany
Hausärzte Dres. Erlinger & Kollegen - Cardiovascular & Metabolic Research
Hausärzte Dres. Erlinger & Kollegen is a primary care research center specializing in cardiovascular disease prevention and metabolic disorder management. The practice focuses on lipid metabolism disorders and therapeutic interventions aimed at reducing cardiovascular risk in high-risk patient populations.
- Hypercholesterolemia management and LDL-cholesterol reduction therapies
- Novel lipid-lowering treatments including PCSK9 inhibitors
- Patient-centered outcomes research and quality of life assessments
The center actively investigates advanced treatment strategies for hypercholesterolemia, with particular emphasis on achieving individualized LDL-cholesterol targets in patients requiring intensive lipid management. Their research portfolio includes evaluation of innovative therapies such as inclisiran, examining both clinical efficacy and real-world patient outcomes when combined with optimized lipid-lowering therapy regimens.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hausärzte Dres. Erlinger & Kollegen
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase IV Randomized, Double-Blind, Placebo-Controlled Study of Inclisiran with Lipid-Lowering Therapy in Hypercholesterolemia Patients | Novartis Pharma AG | Phase III | Not Recruiting | Apr 2022 | Mar 2025 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 1 | Unknown | 2022-04-08 | 2022-04-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.